These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

600 related articles for article (PubMed ID: 17433425)

  • 1. Significant differences of lymphocytes isolated from ascites of patients with ovarian cancer compared to blood and tumor lymphocytes. Association of CD3+CD56+ cells with platinum resistance.
    Bamias A; Tsiatas ML; Kafantari E; Liakou C; Rodolakis A; Voulgaris Z; Vlahos G; Papageorgiou T; Tsitsilonis O; Bamia C; Papatheodoridis G; Politi E; Archimandritis A; Antsaklis A; Dimopoulos MA
    Gynecol Oncol; 2007 Jul; 106(1):75-81. PubMed ID: 17433425
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlation of NK T-like CD3+CD56+ cells and CD4+CD25+(hi) regulatory T cells with VEGF and TNFalpha in ascites from advanced ovarian cancer: Association with platinum resistance and prognosis in patients receiving first-line, platinum-based chemotherapy.
    Bamias A; Koutsoukou V; Terpos E; Tsiatas ML; Liakos C; Tsitsilonis O; Rodolakis A; Voulgaris Z; Vlahos G; Papageorgiou T; Papatheodoridis G; Archimandritis A; Antsaklis A; Dimopoulos MA
    Gynecol Oncol; 2008 Feb; 108(2):421-7. PubMed ID: 18036640
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma.
    Freedman RS; Kudelka AP; Kavanagh JJ; Verschraegen C; Edwards CL; Nash M; Levy L; Atkinson EN; Zhang HZ; Melichar B; Patenia R; Templin S; Scott W; Platsoucas CD
    Clin Cancer Res; 2000 Jun; 6(6):2268-78. PubMed ID: 10873077
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer.
    Woo EY; Chu CS; Goletz TJ; Schlienger K; Yeh H; Coukos G; Rubin SC; Kaiser LR; June CH
    Cancer Res; 2001 Jun; 61(12):4766-72. PubMed ID: 11406550
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Decrease in intrahepatic CD56+ lymphocytes in gastric and colorectal cancer patients with liver metastases.
    Gulubova M; Manolova I; Kyurkchiev D; Julianov A; Altunkova I
    APMIS; 2009 Dec; 117(12):870-9. PubMed ID: 20078551
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of inhibitory receptors in natural killer (CD3(-)CD56(+)) cells and CD3(+)CD56(+) cells in the peripheral blood lymphocytes and tumor infiltrating lymphocytes in patients with primary hepatocellular carcinoma.
    Yuen MF; Norris S
    Clin Immunol; 2001 Dec; 101(3):264-9. PubMed ID: 11726217
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alterations in expression and function of signal-transducing proteins in tumor-associated T and natural killer cells in patients with ovarian carcinoma.
    Lai P; Rabinowich H; Crowley-Nowick PA; Bell MC; Mantovani G; Whiteside TL
    Clin Cancer Res; 1996 Jan; 2(1):161-73. PubMed ID: 9816103
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor cytolysis by lymphocytes infiltrating ovarian malignant ascites.
    Ioannides CG; Platsoucas CD; Rashed S; Wharton JT; Edwards CL; Freedman RS
    Cancer Res; 1991 Aug; 51(16):4257-65. PubMed ID: 1868446
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ovarian cancer-associated ascites demonstrates altered immune environment: implications for antitumor immunity.
    Giuntoli RL; Webb TJ; Zoso A; Rogers O; Diaz-Montes TP; Bristow RE; Oelke M
    Anticancer Res; 2009 Aug; 29(8):2875-84. PubMed ID: 19661290
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased frequency of CD4+ cells expressing CD161 in cancer patients.
    Iliopoulou EG; Karamouzis MV; Missitzis I; Ardavanis A; Sotiriadou NN; Baxevanis CN; Rigatos G; Papamichail M; Perez SA
    Clin Cancer Res; 2006 Dec; 12(23):6901-9. PubMed ID: 17145807
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients.
    Fu J; Xu D; Liu Z; Shi M; Zhao P; Fu B; Zhang Z; Yang H; Zhang H; Zhou C; Yao J; Jin L; Wang H; Yang Y; Fu YX; Wang FS
    Gastroenterology; 2007 Jun; 132(7):2328-39. PubMed ID: 17570208
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD4(+)CD25(+)CD127(low/-) regulatory T cells express Foxp3 and suppress effector T cell proliferation and contribute to gastric cancers progression.
    Shen LS; Wang J; Shen DF; Yuan XL; Dong P; Li MX; Xue J; Zhang FM; Ge HL; Xu D
    Clin Immunol; 2009 Apr; 131(1):109-18. PubMed ID: 19153062
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lymphocyte recovery in advanced ovarian cancer patients after high-dose chemotherapy and peripheral blood stem cell plus growth factor support: clinical implications.
    Ferrandina G; Pierelli L; Perillo A; Rutella S; Ludovisi M; Leone G; Mancuso S; Scambia G
    Clin Cancer Res; 2003 Jan; 9(1):195-200. PubMed ID: 12538469
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The correlation between the percent of CD3- CD56+ cells and NK precursor function.
    Gharehbaghian A; Donaldson C; Newman J; Bannister G; Bradley BA
    Iran J Allergy Asthma Immunol; 2006 Dec; 5(4):167-75. PubMed ID: 17237569
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The frequency of regulatory CD3+CD8+CD28- CD25+ T lymphocytes in human peripheral blood increases with age.
    Simone R; Zicca A; Saverino D
    J Leukoc Biol; 2008 Dec; 84(6):1454-61. PubMed ID: 18780874
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phenotyping of lymphocytes expressing regulatory and effector markers in infiltrating ductal carcinoma of the breast.
    Leong PP; Mohammad R; Ibrahim N; Ithnin H; Abdullah M; Davis WC; Seow HF
    Immunol Lett; 2006 Feb; 102(2):229-36. PubMed ID: 16246429
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proportion of CD4+CD25+ regulatory T cell is increased in the patients with ovarian carcinoma.
    Li X; Ye DF; Xie X; Chen HZ; Lu WG
    Cancer Invest; 2005; 23(5):399-403. PubMed ID: 16193639
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increase of regulatory T cells in the peripheral blood of cancer patients.
    Wolf AM; Wolf D; Steurer M; Gastl G; Gunsilius E; Grubeck-Loebenstein B
    Clin Cancer Res; 2003 Feb; 9(2):606-12. PubMed ID: 12576425
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased populations of regulatory T cells in peripheral blood and tumor-infiltrating lymphocytes in patients with gastric and esophageal cancers.
    Ichihara F; Kono K; Takahashi A; Kawaida H; Sugai H; Fujii H
    Clin Cancer Res; 2003 Oct; 9(12):4404-8. PubMed ID: 14555512
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Detection of lymphocyte subsets in the peripheral blood of patients with malignant ovarian tumors].
    Liu M; Xie J; Zhao S
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2014 Jun; 30(6):627-9, 634. PubMed ID: 24909286
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.